126 related articles for article (PubMed ID: 1431308)
41. Orientation of a human leukocyte interferon molecule on its cell surface receptor: carboxyl terminus remains accessible to a monoclonal antibody made against a synthetic interferon fragment.
Arnheiter H; Ohno M; Smith M; Gutte B; Zoon KC
Proc Natl Acad Sci U S A; 1983 May; 80(9):2539-43. PubMed ID: 6302694
[TBL] [Abstract][Full Text] [Related]
42. Immunological activities of recombinant interferon-alpha 2 and its A fragment.
Attallah AM; Fleisher TA; Hu R; Abdel-Gaffar H; Ibrahim S; Metwali A; Zoon K
J Interferon Res; 1987 Apr; 7(2):223-9. PubMed ID: 3611842
[TBL] [Abstract][Full Text] [Related]
43. Natural killer cell activity against cultured melanoma cells: a dye-reduction technique with studies on augmented activity by interferon subtypes.
Losinno C; Wines BD; Johns TG; Mackay IR
Nat Immun; 1992; 11(4):215-24. PubMed ID: 1384830
[TBL] [Abstract][Full Text] [Related]
44. Definition of receptor binding domains in interferon-alpha.
Fish EN
J Interferon Res; 1992 Aug; 12(4):257-66. PubMed ID: 1431305
[TBL] [Abstract][Full Text] [Related]
45. Interferon-alpha: a gene family in therapeutic use.
Lundgren E; Kandefer-Szerszen M; Andersson G; Ekre HP
J Pharm Biomed Anal; 1989; 7(2):233-8. PubMed ID: 2562206
[TBL] [Abstract][Full Text] [Related]
46. Behavior of a cloned murine interferon alpha/beta receptor expressed in homospecific or heterospecific background.
Uzé G; Lutfalla G; Bandu MT; Proudhon D; Mogensen KE
Proc Natl Acad Sci U S A; 1992 May; 89(10):4774-8. PubMed ID: 1533935
[TBL] [Abstract][Full Text] [Related]
47. A comparison of the neutralizing properties of monoclonal and polyclonal antibodies to human interferon alpha.
Exley T; Parti S; Barwick S; Meager A
J Gen Virol; 1984 Dec; 65 ( Pt 12)():2277-80. PubMed ID: 6512507
[TBL] [Abstract][Full Text] [Related]
48. Atypical spI interferon binds on porcine cells to a major component of type I interferon receptor.
Niu PD; Lefevre F; La Bonnardiere C
J Interferon Cytokine Res; 1995 Sep; 15(9):769-75. PubMed ID: 8536104
[TBL] [Abstract][Full Text] [Related]
49. Kinetic evidence for an activation step following binding of human interferon alpha 2 to the membrane receptors of Daudi cells.
Mogensen KE; Bandu MT
Eur J Biochem; 1983 Aug; 134(2):355-64. PubMed ID: 6307693
[TBL] [Abstract][Full Text] [Related]
50. Electrostatic interactions in the cellular dynamics of the interferon-receptor complex.
Uze G; Bandu MT; Eid P; Grütter M; Mogensen KE
Eur J Biochem; 1988 Feb; 171(3):683-91. PubMed ID: 2964368
[TBL] [Abstract][Full Text] [Related]
51. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
52. Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) omega 1: evidence that IFN-omega 1 is a component of human leukocyte IFN.
Adolf GR
Virology; 1990 Apr; 175(2):410-7. PubMed ID: 1691561
[TBL] [Abstract][Full Text] [Related]
53. Differential responsiveness of cloned mammary carcinoma cell populations to the human recombinant leukocyte interferon enhancement of tumor antigen expression.
Greiner JW; Tobi M; Fisher PB; Langer JA; Pestka S
Int J Cancer; 1985 Aug; 36(2):159-66. PubMed ID: 3160671
[TBL] [Abstract][Full Text] [Related]
54. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
55. [Biological activity of human alpha-interferons studied using specific antisera].
Korsun NS; Nosik DN; Novokhatskiĭ AS; Trushinskaia GN
Antibiot Khimioter; 1988 Nov; 33(11):827-30. PubMed ID: 2465745
[TBL] [Abstract][Full Text] [Related]
56. Structure-function analysis of human IFN-alpha. Mapping of a conformational epitope by homologue scanning.
Wang L; Hertzog PJ; Galanis M; Overall ML; Waine GJ; Linnane AW
J Immunol; 1994 Jan; 152(2):705-15. PubMed ID: 7506733
[TBL] [Abstract][Full Text] [Related]
57. Characterization of the human type I interferon receptor by ligand blotting.
Schwabe M; Princler GL; Faltynek CR
Eur J Immunol; 1988 Dec; 18(12):2009-14. PubMed ID: 2975600
[TBL] [Abstract][Full Text] [Related]
58. Epitope mapping of human recombinant interferon alpha molecules by monoclonal antibodies.
Alkan SS; Braun DG
Ciba Found Symp; 1986; 119():264-78. PubMed ID: 2426055
[TBL] [Abstract][Full Text] [Related]
59. Radiolabeling of the interferon-alpha receptor.
Langer JA
Biochem Biophys Res Commun; 1988 Dec; 157(3):1264-70. PubMed ID: 2974697
[TBL] [Abstract][Full Text] [Related]
60. Evidence for glycosphingolipid modification of the type 1 IFN receptor.
Ghislain J; Lingwood CA; Fish EN
J Immunol; 1994 Oct; 153(8):3655-63. PubMed ID: 7930586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
